A RARE-DISEASE DRUG REPORTED ZERO NEW BONE LESIONS THROUGH 84 WEEKS.
In the OPTIMA extension, adults who stayed on Pasatru had no new lesions detected between weeks 56 and 84; the placebo group had nine.
Pasatru, an FDA-approved monoclonal antibody for adults with FOP, reported sustained suppression of new abnormal bone growth through an 84-week Phase 3 extension.
WHAT HAPPENED
OPTIMA enrolled 63 adults for a 56-week randomized trial; 58 completed the extension to at least week 84. From week 56 to week 84, investigators observed no new lesions in the Pasatru groups versus nine in placebo. Flare-ups were also lower, but skin and soft-tissue infections rose with dose.
WHY THIS IS HOPESLOP
FOP is relentlessly progressive and extraordinarily rare. An approved treatment showing durable control of new lesions changes the horizon from merely managing damage to preventing some of it.
ORIGINAL SOURCERegeneron / The LancetRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.